Argonne maintains a wide-ranging science and technology portfolio that seeks to address complex challenges in interdisciplinary and innovative ways. Below is a list of all articles, highlights, profiles, projects, and organizations related specifically to diseases.
The National Science Foundation funded Argonne and others to study the COVID-19 experiences of public health officials and stakeholders. By improving prediction and prevention, they hope to avoid reinventing a wheel no one wants rolling back into town.
Antibody therapies have a variety of uses, but we need to know which therapies work and which ones don’t. Recent research has discovered a means to determine how effective certain antibodies can be in medical scenarios.
Arexvy has been shown to prevent severe illness brought on by respiratory syncytial virus, which affects millions every year. The U.S. Food and Drug Administration has approved Arexvy for people 60 years old or older.
Argonne National Laboratory has developed computer models to predict how disease can spread. With funding from the U.S. Department of Energy, it will work with Sandia National Laboratories algorithms to make them better.